Tumor ablation by gene-modified T cells in the absence of autoimmunity

Cancer Research

Volumn 70, Issue 23, 2010, Pages 9591-9598

  Wang, Leanne X J ^a   Westwood, Jennifer A ^a   Moeller, Maria ^a   Duong, Connie P M ^a   Wei, Wei Zen ^b   Malaterre, Jordane ^a   Trapani, Joseph A ^a,c   Neeson, Paul ^a   Smyth, Mark J ^a,c   Kershaw, Michael H ^a,c,d   Darcy, Phillip K ^a,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CANCER SURVIVAL; CANCER THERAPY; CELL THERAPY; CONTROLLED STUDY; DNA MODIFICATION; FEMALE; HUMAN; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAFETY; T LYMPHOCYTE; THERAPY EFFECT; TRANSGENIC MOUSE; TREATMENT OUTCOME; TUMOR ABLATION; TUMOR GROWTH;

ADOPTIVE TRANSFER; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; AUTOIMMUNITY; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; SURVIVAL ANALYSIS; T-LYMPHOCYTES; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 78649977194     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-10-2884     Document Type: Article

References (40)

1. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004;10:909-15.
2. Malmberg KJ. Effective immunotherapy against cancer: a question of overcoming immune suppression and immune escape?Cancer Immunol Immunother 2004;53:879-92.
3. Blattman JN, Greenberg PD. Cancer immunotherapy: a treatment for the masses. Science 2004;305:200-5.
4. Kershaw MH, Jackson JT, Haynes NM, et al. Gene-engineered T cells as a superior adjuvant therapy for metastatic cancer. J Immunol 2004;173:2143-50.
5. Kershaw MH, Westwood JA, Hwu P. Dual-specific T cells combine proliferation and antitumor activity. Nat Biotechnol 2002;20:1221-7. (Pubitemid 35462486)
6. Cheadle EJ, Gilham DE, Thistlethwaite FC, Radford JA, Hawkins RE. Killing of non-Hodgkin lymphoma cells by autologous CD19 engineered T cells. Br J Haematol 2005;129:322-32.
7. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 2002;20:70-5. (Pubitemid 34044918)
8. Westwood JA, Smyth MJ, Teng MW, Moeller M, Trapani JA, Scott AM, et al. Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice. Proc Natl Acad Sci U S A 2005;102:19051-6.
9. Hombach A, Schlimper C, Sievers E, Frank S, Schild HH, Sauerbruch T, et al. A recombinant anti-carcinoembryonic antigen immunoreceptor with combined CD3zeta-CD28 signalling targets T cells from colorectal cancer patients against their tumour cells. Gut 2006;55:1156-64. (Pubitemid 44085685)
10. + helper T cells induces potent primary and secondary tumor rejection. Blood 2005;106:2995-3003.
11. Ridolfi L, Ridolfi R, Riccobon A, De Paola F, Petrini M, Stefanelli M, et al. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. J Immunother 2003;26:156-62. (Pubitemid 36292786)
12. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 2009;114:535-46.
13. Lamers CH, Sleijfer S, Vulto AG, Kruit WH, Kliffen M, Debets R, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol 2006;24:e20-2.
14. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843-51.
15. Piechocki MP, Ho YS, Pilon S, Wei WZ. Human ErbB-2 (Her-2) transgenic mice: a model system for testing Her-2 based vaccines. J Immunol 2003;171:5787-94.
16. Wels W, Harwerth IM, Mueller M, Groner B, Hynes NE. Selective inhibition of tumor cell growth by a recombinant single-chain antibody toxin specific for the erbB-2 receptor. Cancer Res 1992;52:6310-7.
17. Darcy PK, Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, et al. Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL. J Immunol 2000;164:3705-12. (Pubitemid 30169826)
18. Haynes NM, Snook MB, Trapani JA, Cerruti L, Jane SM, Smyth MJ, et al. Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma. J Immunol 2001;166:182-7. (Pubitemid 32038431)
19. Cheadle EJ, Hawkins RE, Batha H, O'Neill AL, Dovedi SJ, Gilham DE. Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells. J Immunol 2010;184:1885-96.
20. Haynes NM, Trapani JA, Teng MW, Jackson JT, Cerruti L, Jane SM, et al. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood 2002;100:3155-63. (Pubitemid 35217063)
21. Moeller M, Haynes NM, Trapani JA, Teng MW, Jackson JT, Tanner JE, et al. A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells. Cancer Gene Ther 2004;11:371-9. (Pubitemid 38586093)
22. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-57.
23. Chang AE, Shu SY, Chou T, Lafreniere R, Rosenberg SA. Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors. Cancer Res 1986;46:3426-30. (Pubitemid 16096884)
24. Hu HM, Poehlein CH, Urba WJ, Fox BA. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res 2002;62:3914-9.
25. + T cell memory. Proc Natl Acad Sci U S A 2004;101:9357-62.
26. Press MF, Cordon-Cardo C, Slamon DJ. Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 1990;5:953-62.
27. Olayioye MA. Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res 2001;3:385-9.
28. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989;244:707-12. (Pubitemid 19147683)
29. Yu D, Hung MC. Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 2000;19:6115-21. (Pubitemid 32059461)
30. Tzahar E, Yarden Y. The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. Biochim Biophys Acta 1998;1377:M25-37.
31. de Witte MA, Coccoris M, Wolkers MC, van den Boom MD, Mesman EM, Song JY, et al. Targeting self-antigens through allogeneic TCR gene transfer. Blood 2006;108:870-7. (Pubitemid 44154619)
32. Bos R, van Duikeren S, Morreau H, Van den boom MD, Mesman EM, Song JY, et al. Balancing between antitumor efficacy and autoimmune pathology in T-cell-mediated targeting of carcinoembryonic antigen. Cancer Res 2008;68:8446-55.
33. Ugel S, Scarselli E, Iezzi M, Mennuni C, Pannellini T, Calvaruso F, et al. Autoimmune B-cell lymphopenia after successful adoptive therapy with telomerase-specific T lymphocytes. Blood 2010;115:1374-84.
34. Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, et al. Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med 2000;192:1637-44.
35. Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, et al. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A 2008;105:8061-6.
36. Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nahrig J, et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 2008;57:271-80. (Pubitemid 350159915)
37. Brentjens R, Yeh R, Bernal Y, Riviere I, Sadelain M. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther 2010;18:666-8.
38. Cohen JL, Boyer O, Thomas-Vaslin V, Klatzmann D. Suicide gene-mediated modulation of graft-versus-host disease. Leuk Lymphoma 1999;34:473-80. (Pubitemid 29429728)
39. Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood 2001;97:1249-57. (Pubitemid 32183746)
40. Tey SK, Dotti G, Rooney CM, Heslop HE, Brenner MK. Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantation. Biol Blood Marrow Transplant 2007;13:913-24. (Pubitemid 47055386)